Unusual Management of a Rare Case of Methimazole-Resistant Graves Disease.

JCEM case reports Pub Date : 2024-12-19 eCollection Date: 2025-01-01 DOI:10.1210/jcemcr/luae235
Michael Tang, Bashar Fteiha, Shumei Meng
{"title":"Unusual Management of a Rare Case of Methimazole-Resistant Graves Disease.","authors":"Michael Tang, Bashar Fteiha, Shumei Meng","doi":"10.1210/jcemcr/luae235","DOIUrl":null,"url":null,"abstract":"<p><p>As the leading cause of hyperthyroidism, Graves disease (GD) does not often present with its classical triad of pretibial myxedema, goiter, and exophthalmos but instead is often recognized by various manifestations such as tachycardia, weight loss, jaundice, or dermatopathy and requires utmost clinical vigilance. Three treatment modalities for GD exist as antithyroid drugs (ATDs), radioactive iodine (RAI), and surgery, but each bears its own serious side effects. Furthermore, there have been several reports in the literature about ATD resistance that can complicate management. We describe a rare complex case of methimazole (MMI)-resistant GD in a 58-year-old woman with multiple comorbidities including heart failure, atrial fibrillation, liver cirrhosis, and hypertension. She presented with an initial complaint of diffuse swelling and was found to have severe thyrotoxicosis. Despite high doses of MMI, her thyroid function remained significantly elevated. Thyroid uptake and scan while on MMI showed high radioactive iodine uptake. After receiving RAI therapy, her thyroid function and bilirubin improved markedly, liver enzymes remained stable, and anasarca responded to diuretics. This case highlights the challenges in managing resistant GD and emphasizes the necessity of personalized treatment plans.</p>","PeriodicalId":73540,"journal":{"name":"JCEM case reports","volume":"3 1","pages":"luae235"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656567/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCEM case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jcemcr/luae235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

As the leading cause of hyperthyroidism, Graves disease (GD) does not often present with its classical triad of pretibial myxedema, goiter, and exophthalmos but instead is often recognized by various manifestations such as tachycardia, weight loss, jaundice, or dermatopathy and requires utmost clinical vigilance. Three treatment modalities for GD exist as antithyroid drugs (ATDs), radioactive iodine (RAI), and surgery, but each bears its own serious side effects. Furthermore, there have been several reports in the literature about ATD resistance that can complicate management. We describe a rare complex case of methimazole (MMI)-resistant GD in a 58-year-old woman with multiple comorbidities including heart failure, atrial fibrillation, liver cirrhosis, and hypertension. She presented with an initial complaint of diffuse swelling and was found to have severe thyrotoxicosis. Despite high doses of MMI, her thyroid function remained significantly elevated. Thyroid uptake and scan while on MMI showed high radioactive iodine uptake. After receiving RAI therapy, her thyroid function and bilirubin improved markedly, liver enzymes remained stable, and anasarca responded to diuretics. This case highlights the challenges in managing resistant GD and emphasizes the necessity of personalized treatment plans.

罕见甲巯咪唑耐药Graves病的异常处理。
作为甲状腺功能亢进的主要原因,Graves病(GD)并不经常表现为胫前黏液水肿、甲状腺肿和眼球突出等典型的三联征,而是经常表现为心动过速、体重减轻、黄疸或皮肤病等,需要高度警惕。GD有三种治疗方式:抗甲状腺药物(ATDs)、放射性碘(RAI)和手术,但每种治疗方式都有其严重的副作用。此外,文献中也有一些关于ATD耐药性的报道,这可能会使治疗复杂化。我们描述了一个罕见的复杂病例甲巯咪唑(MMI)耐药GD在一个58岁的女性多重合并症,包括心力衰竭,心房颤动,肝硬化和高血压。她最初的主诉是弥漫性肿胀,后来发现有严重的甲状腺毒症。尽管高剂量的MMI,她的甲状腺功能仍然明显升高。甲状腺摄取和MMI扫描显示高放射性碘摄取。接受RAI治疗后,患者甲状腺功能和胆红素明显改善,肝酶保持稳定,anasarca对利尿剂有反应。本病例强调了管理耐药GD的挑战,并强调了个性化治疗计划的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信